LifeStance Reports First Quarter 2025 Results

19 hours ago

SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers…

FAU BEPI Poll: Hispanic Economic Outlook Sinks Ahead of Tariffs, Rising Prices

19 hours ago

BOCA RATON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- As households face increasing prices for goods and talk of new…

Radware Reports First Quarter 2025 Financial Results

19 hours ago

First Quarter 2025 Financial Results and Highlights Revenue of $72.1 million, an increase of 11% year-over-yearCloud ARR of $80 million,…

Stella-Jones Grows Into Electrical Transmission Steel Structures With the Acquisition of Locweld

19 hours ago

Company delivering on its strategy to expand infrastructure offeringMONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Stella-Jones Inc. (TSX: SJ) (“Stella-Jones”…

Axalta Releases First Quarter 2025 Results

19 hours ago

PHILADELPHIA, May 07, 2025 (GLOBE NEWSWIRE) -- Axalta Coating Systems Ltd. (NYSE:AXTA) (“Axalta”), a leading global coatings company, announced its…

Magnera Reports Second Quarter Results – Provides Updated Outlook

19 hours ago

Second Quarter Highlights GAAP: Net sales of $824 million, Operating income of $4 millionNon-GAAP: Adjusted EBITDA of $89 million, Post-merger…

Nokia Corporation – Managers’ transactions (Ihamuotila)

19 hours ago

Nokia CorporationManagers’ transactions7 May 2025 at 12:20 EESTNokia Corporation - Managers' transactions (Ihamuotila)Transaction notification under Article 19 of EU Market…

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025

20 hours ago

REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the…

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025

20 hours ago

Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients…

Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Results at ARVO 2025

20 hours ago

Innovative antisense therapy blocking production of TGF-β2 shows promise in reducing retinal fibrosis and improving outcomes in patients with wet…

This website uses cookies.